PRESS RELEASES

Year
December 08 | 2022
RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer
November 30 | 2022
RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress
November 17 | 2022
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
November 17 | 2022
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
November 10 | 2022
RAPT Therapeutics Reports Third Quarter 2022 Financial Results
November 09 | 2022
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences
September 28 | 2022
RAPT Therapeutics Strengthens Leadership Team with Two New Key Hires
August 31 | 2022
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September
August 11 | 2022
RAPT Therapeutics Reports Second Quarter 2022 Financial Results
May 25 | 2022
RAPT Therapeutics Announces Private Placement Financing of $50 Million
May 23 | 2022
RAPT Therapeutics Announces Initiation of Phase 2b Trial of RPT193 in Patients with Moderate-to-Severe Atopic Dermatitis
May 11 | 2022
RAPT Therapeutics Reports First Quarter 2022 Financial Results
May 04 | 2022
RAPT Therapeutics Expands Leadership Team with Multiple Key Hires
March 28 | 2022
RAPT Therapeutics Announces Biomarker Data from Phase 1b Trial of RPT193 Consistent with Disease Modification in Atopic Dermatitis
March 10 | 2022
RAPT Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results
February 09 | 2022
RAPT Therapeutics to Participate in the 11th Annual SVB Leerink Healthcare Conference
January 04 | 2022
RAPT Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference